Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When co-Administered With GSK Biologicals' MMRV Vaccine (Priorix-Tetra™) in Healthy 12 to 23-Month-Old Children
Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine
109670
NCT00474266
Infections, Meningococcal
Phase 3
 
A follow on study 112036 was conducted.
May 2013

Powered by ideaPoint, Inc.